Abstract
A meta-analysis based on randomized controlled trials was conducted to clarify the effect of psychobiotics on depression in adults. The main result of concern is the score of the psychometric questionnaires. The outcomes were extracted using standardized mean difference (SMD) from each study, based on a random-effects model. Psychobiotic treatment results in a higher depression score reduction compared with the placebo. The observed SMDs ranged from −0.673 to 1.011, with most estimates being positive (63%). The estimated average SMD based on the random-effects model was 0.19 (95% confidence interval: 0.01–0.37), with the average outcome differed significantly from zero (Z = 2.018, P = 0.044). The subgroup analysis indicated that psychobiotics are advisable to be delivered in solid formulations with multiple probiotic strains and used in age-appropriate depressed patients. Collectively, psychobiotics showed great potential in managing mental health when appropriately administered.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
